Expert Interview
A Third View: Discussing UCB's Phase 3 studies (BE HEARD I and BE HEARD II) evaluating the efficacy and safety of bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa (HS)
Ticker(s): UCB- Specializes in medical dermatoloqv, sexually transmitted diseases, genital dermatology,
and infectious diseases of the skin. - Interim Chairman of the Department of Dermatology at Mount Sinai
Beth Israel - Assistant Professor of Dermatology at the Icahn School of Medicine at Mount Sinai
- Director of the Adult Dermatology Consultation Service at Mount Sinai Beth Israel.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
